Chalazion (cyst): Symptoms, pictures, causes, and treatment
Modulating Conjunctival Wound Healing
Thylefors B, Negrel A . The global impact of glaucoma. Bull World Health Org 1994;72:323–6
Foster A, Johnson G . Magnitude and causes of blindness in the developing world. Int Ophthalmol 1990;14:135–40
Quigley H . Number of people with glaucoma worldwide [see comments]. Br J OphthalmoI 1996;80:389–93
Sommer A . Glaucoma: facts and figures. Doyne Lecture. Eye 1996;10:295–301
Jay J . Rational choice of therapy in primary open angle glaucoma. Eye 1992;6:243–7
Migdal C, Gregory W, Hitchings R Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651–6
Addicks E, Quigley H, Green W, Robin A . Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983;101:795–8
Hitchings R, Grierson I . Clinicopathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK 1983;103:84–8
Stamper R, McMenemy M, Lieberman M . Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol 1992;114:544–53
Parrish R, Minckler D . 'Late endophthalmitis': filtering surgery time bomb? Ophthalmology 1996:103:1167–8.
Jampel H, Pasquale L, Dibernardo C Hypotony maculopathy following trabeculectomy with mitomycin C Arch Ophthalmol 1992;110:1049–50.
The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol 1989;108:625–35
Katz G, Higginbotham E, Lichter P, Skuta G, Musch D, Bergstrom T, et al . Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery: extended follow-up. Ophthalmology 1995;102:1263–9
Kitazawa Y, Kawase K, Matsushita H, Minobe M . Trabeculectomy with mitomycin: a comparative study with fluorouracil. Arch Ophthalmol 1991;109:1693–8
Lamping K, Belkin J . 5-Fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology 1995;102:70–5
Khaw P, Doyle J, Sherwood M, Grierson I, Schultz G, McGorray S . Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Arch Ophthalmol 1993;111:263–7
Crowston J, Akbar A, Constable P, Occleston N, Daniels J, Khaw P . Antimetabolites-induced apoptosis in Tenon' capsule fibroblasts. Invest Ophthalmol Vis Sci 1998;39:449–54
Singer A, Clarke RA . Cutaneous wound healing. N Engl J Med 1999;341:738–46
Clark R, Henson P . The molecular and cellular biology of wound repair. New York: Plenum Press, 1988.
Reichel M, Ali R, Thrasher A, Hunt D, Bhattacharya S, Baker D . Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Ther 1998;5:1038–46
Khaw P, Occleston N, Schultz G, Grierson I, Sherwood M, Larkin G . Activation and suppression of fibroblast function. Eye 1994;8:188–95
Occleston N, Tarnuzzer R, Munro P, Ravetto P, Ali R, Schultz G, et al . Inhibition of matrix metalloproteinase activity inhibits Tenon' capsule fibroblast mediated collagen contraction. Invest Ophthalmol Vis Sci 1995;36:S877.
Scott K, Wood E, Karran E . A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. FEBS Lett 1998;441:137–40
Desmouliere A, Redard M, Darby I, Gabbiani G . Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:56..6.
Liu B, Connolly M . The pathogenesis of cutaneous fibrosis. Semin Cutan Med Surg 1998;17:3–11
Fini E . Keratocyte and fibroblast phenotypes in the repairing cornea. Prog Retinal Eye Res 1999;18:529–51
Broadway D, Grierson I, O'Brien C, Hitchings R . Adverse effects of topical anti-glaucomatous medication regimens. I. Effect on the cell profile of the conjunctiva. Arch Ophthalmol 1994;112:1446–54
Broadway D, Grierson I, O'Brien C, Hitchings R . Adverse effects of topical antiglaucoma medication regimens. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1437–45
Broadway D, Grierson I, O'Brien C, Hitchings RA . Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch OphthalmoI 1996;114:262–7
Gwynn D, Stewart W, Pitts R, McMillian T, Hennis H . Conjunctival structure and cell counts and the results of filtering surgery. Am J Ophthalmol 1993;116:464–8
Nuzzi R, Vercelli A, Finazzo C, Cracco C . Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatments: an immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 1995;233:154–62
Occleston N, Alexander R, Mazure A, Larkin G, Khaw P . Effects of single exposures to antiproliferative agents on ocular fibroblast-mediated collagen contraction. Invest Ophthalmol Vis Sci 1994;35:3681–90
Occleston N, Daniels J, Tarnuzzer R, Sethi K, Alexander R, Bhattacharya S, et al . Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behaviour. Invest Ophthalmol Vis Sci 1997;38:1998–2007
Daniels J, Occleston N, Crowston J, Khaw P . Effects of antimetabolite induced cellular growth arrest on fibroblast-fibroblast interactions. Exp Eye Res 1999;69:117–27
Waterman-Storer C, Worthylake R, Liu B, Burridge K, Salmon E . Microtubule growth activates Rac1 to promote lamellipodial protrusion in fibroblasts. Nature Cell BioI 1999;1:45–50
Metcalfe R, Weetman A . Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmology. Clin Endocrinol 1994;40:67–72
Joseph J, Grierson I, Hitchings R . Taxol, cytochalasin B and colchicine effects on fibroblast migration and contraction: a role in glaucoma filtration surgery? Curr Eye Res 1989:8:203–15.
Jampel H, Moon J . The effect of paclitaxel powder on glaucoma filtration surgery in rabbits. J Glaucoma 1998;7:170–7
Jampel H, Thibault D, Leong K, Uppal P, Quigley H . Glaucoma filtration surgery in non-human primates using taxol and etoposide in polyanhydride carriers. Invest Ophthalmol Vis Sci 1993;34:3076–83
Blagosoklonny M, Fojo T . Molecular effects of paclitaxel: myths and reality. Int J Cancer 1999;83:151–6
Pleass R, Khaw P . Inhibition of remodelling and contraction in ocular wound healing. Keystone Symposium: Ocular cell and molecular biology, Colorado, 1999:37.
Daniels J, Khaw P . Synthetic matrix metalloproteinase inhibitor reduces contraction of cultured ocular tissue. Eur J Plast Surg 2000;in press.
Pilcher B, Wang M, Qin X, Parks W, Senior R, Welgus H . Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann N Y Acad Sci 1999;878:12–24
Skotnicki J, Zask A, Nelson F, Albright J, Levin J . Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci 1999;878:61–72
De B, Natchus M, Cheng M, Pikul S, Almstead N, Taiwo Y, et al . The next generation of MMP inhibitors: design and synthesis. Ann N Y Acad Sci 1999;878:40–60
McGuigan L, Mason R, Sanchez R, Quigley H . D-Penicillamine and beta-aminoproponitrile effects on experimental filtering surgery. Invest Ophthalmol Vis Sci 1987;28:1625–9
Blumenkranz M, Ophir A, Claflin A, Hajek A . Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol 1982;94:458–67
Blumenkranz M, Hartzer M, Hajek A . Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol 1987;105:396–9
Chen C . Enhanced intraocular pressure controlling effectiveness of trabeculectomy by local application of mitomycin-C. Trans Asia Pacif Acad Ophthalmol 1983;9:172–7
Doyle J, Sherwood M, Khaw P, McGoray S, Smith M . Intraoperative 5-fluorouracil for filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 1993;34:3313–9
Khaw P, Sherwood M, MacKay S, Rossi M, Schultz G . Five- minute treatments with fluorouracil, floxuridine and mitomycin have long-term effects on human Tenon' capsule fibroblasts. Arch Ophthalmol 1992;110:1150–4
Honjo M, Tanihara H, Inatani M, Honda Y . Mitomycin C trabeculectomy in eyes with cicatricial conjunctiva. Am J Ophthalmol 1998;126:823–4
Ali-Hazmi A, Zwann J, Awad A, Al-Mesfer S, Mullaney P . Effectiveness and complications of mitomycin C use during pediatric glaucoma surgery. Ophthalmology 1998;105:1915–20
Beck A, Wilson W, Lynch M, Lynn M, Noe R . Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Am J Ophthalmol 1998;126:648–57
Khaw P . What is the best primary surgical treatment for the infantile glaucomas? Br J Ophthalmol 1996:80:495–6.
Khaw P, Wilkins M, Shah P . Glaucoma surgery. In: Easty D, Sparrow J, editors. Oxford textbook of ophthalmology. Oxford: Oxford University Press, 1999:1211–39.
Shin D, Reed S, Swords R, Reed A, Simone P, Birt C . Cellulose sponge punch for controlled mitomycin application. Arch Ophthalmol 1994;112:1624–5
Wilkins M, Occleston N, Kotecha A, Waters L, Khaw P . Sponge delivery parameters and tissue levels of 5-fluorouracil. Br J Ophthalmol 2000;84:92–7
Mehel E, Weber M, Stork L, Pechereau A . A novel method for controlling the quantity of mitomycin-C applied during filtering surgery for glaucoma. J Ocul Pharmacol Ther 1998;14:491–6
Cordeiro M, Constable P, Alexander R, Bhattacharya S, Khaw P . The effect of varying mitomycin-C treatment area in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 1997;38:1639–46
Miller M, Rice N . Trabeculectomy combined with beta irradiation for congenital glaucoma. Br J Ophthalmol 1991;75:584–90
Constable P, Crowston J, Occleston N, Cordeiro M, Khaw P . Long term growth arrest of human Tenon' fibroblasts following single applications of beta radiation. Br J Ophthalmol 1998;82:448–52
Constable P, Cordeiro M, Crowston J, Khaw P . The effects of single doses of beta irradiation on bleb survival and morphology in a rabbit model of filtration surgery. Invest Ophthalmol Vis Sci 1998;39 (Suppl): abstract no. 3192.
Singh K, Group PTAS . Intraoperative 5-fluorouracil (5FU) vs mitomycin C (MMC): the primary trabeculectomy antimetabolite study. Invest Ophthalmol Vis Sci 1999;40 (Suppl):abstract no.19.
Palmberg P, Escalona E, Norris E, Schiffman J . Long-term follow-up primary filtering surgery with mitomycin or 5-fluorouracil. Invest Ophthalmol Vis Sci 1999;40 (Suppl):abstract no. 1416.
Finley C, Cantor L, Wudunn D, Hoop J, Lakhani V, Alvi N . Comparison of intraoperative 5-fluorouracil versus mitomycin C at six and twelve months in primary trabeculectomy. Invest Ophthalmol Vis Sci 1999;40 (Suppl): abstract no. 5098.
Al-Aswad L, Huang M, Netland P . Inhibition of Tenon' fibroblast proliferation and enhancement of filtration surgery in rabbits with cytosine arabinoside. J Ocul Pharmacol 1999;15:41–9
Denk P, Knorr M . In vitro effect of ascorbic acid on the proliferation of bovine scleral and Tenon' capsule fibroblasts. Eur J Ophthalmol 1998;8:37–41
Maignen F, Tilleul P, Billardon C, Xu-Van Opstal W, Pelaprat D, Elena P, et al. Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex vivo model. J Ocul Pharmacol Ther 1996;12:289–98
Akimoto M, Hangai M, Okazaki K, Kogishi J, Honda Y, Kaneda Y . Growth inhibition of cultured human Tenon' fibroblastic cells by targeting the E2F transcription factor. Exp Eye Res 1998;67:395–401
Wahl S . Glucocorticoids and wound healing. In: Scleimer RP, Claman D, editors. Antiinflammatory steroid action: basic and clinical aspects. New York: Academic Press, 1989:280–302.
Miller M, Grierson I, Unger W, Hitchings R . The effect of topical dexamethasone and preoperative beta irradiation on a model of glaucoma fistulizing surgery in the rabbit. Ophthalmic Surg 1990;21:44–54
Araujo S, Spaeth G, Roth S, Starita R . A ten-year follow-up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy. Ophthalmology 1995;102:1753–9
Giangiacomo J, Dueker D, Adelstein E . The effect of preoperative subconjunctival triamcinolone administration on glaucoma filtration. Arch Ophthalmol 1986;104:838–41
Nguyen K, Lee D . Effect of steroids and nonsteroidal antiinflammatory agents on human ocular fibroblasts. Invest Ophthalmol Vis Sci 1992;33:2693–701
Migdal C, Hitchings R . The developing bleb: effect of topical antiprostaglandins on the outcome of glaucoma fistulizing surgery. Br J Ophthalmol 1983;67:655–60
Snyder R, Lambrou F, Williams G . Intraocular fibrinolysis with recombinant human tissue plasminogen activator: experimental treatment in a rabbit model. Arch Ophthalmol 1987;105:1277–80
Lee P, Myers K, Hsieh M, Wood E, Hotaling D . Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA). J Ocul Pharmacol Ther 1995;11:227–32
Azuara-Blanco A, Wilson R . Intraocular and extraocular bleeding after intracameral injection of tissue plasminogen activator. Br J Ophthalmol 1998;82;1345–6.
Lundy D, Sidoti P, Winarko T, Minckler D, Heuer D . Tissue plasminogen activator after glaucoma surgery: indications, effectiveness, and complications. Ophthalmology 1996;103:274–82
Zwann J, Latimer W . Topical tissue plasminogen activator appears ineffective for the clearance of intraocular fibrin. Ophthalmic Surg Lasers 1998;29:476–83
WuDunn D . Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery. Am J Ophthalmol 1997;124:693–5
Bramsen T . A double-blind study on the influence of tranexamic acid on the intraocular pressure and the central corneal thickness after trabeculectomy for glaucoma simplex. Acta Ophthalmol 1978;56:998–1005
Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D . Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808–12
D'Amore P . Mechanisms of endothelial growth control. Am J Respir Cell Mol Biol 1992;6:1–8
Favard C, Moukadiri H, Dorey C . Praloran V, Plouet J. Purification and biological properties of vasculotropin a new angiogenic cytokine. Biol Cell 1991;73:1–6
Liu J, Razani B, Tang S, Terman B, Ware J, Lisanti M . Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. J Biol Chern 1999;274:15781–5
Furlong R . The biology of hepatocyte growth factor/scatter factor. Bioessays 1992;14:613–7
Paper D . Natural products as angiogenesis inhibitors. Planta Med 1998;64:686–95
Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Skukhatme V . Endostatin induces endothelial cell apoptosis. J Biol Chern 1999;274:11721--6.
O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, et al . Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997;88:277–85
Liekens S, Neyts J, Degreve B, De Clercq E . The sulfonic acid polymers PAMPS poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis. Oncol Res 1997;9:173–91
Wong J, Wang N, Miller J, Schuman J . Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 1994;58:439–51
Akbar A, Salmon M . Cellular environments and apoptosis: tissue microenvironments control activated T cell death. Immunol Today 1997;18:72–6
Ellerby H, Arap W, Ellerby L, Kain R, Andrusiak R, Del Rio G, et al . Anti-cancer activity of targeted pro-apoptosic peptides. Nature 1999;5:1032–8
Gillies M, Brooks A, Young S, Gillies B, Simpson J, Goldberg I . A randomized phase II trial of interferon-alpha 2b versus 5-fluorouracil after trabeculectomy. Aust N Z J Ophthalmol 1999;27:37–44
Nguyen K, Hoang A, Lee D . Transcriptional control of human Tenon' capsule fibroblast collagen synthesis in vitro by gamma-interferon. Invest Ophthalmol Vis Sci 1989;35:3064–70
Duncan M, Berman B . Differential regulation of collagen, glycosaminoglycan, fibronectin, and collagenase activity production in cultured human adult dermal fibroblasts by interleukin 1-alpha and beta and tumor necrosis factor- alpha and beta. J Invest Dermatol 1989;92:699–706
Berman B, Duncan M . Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989;21:694–702
Kahan A, Amor B, Menkes C, Strauch G . Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 1989;87:273–7
Petri J, Schurk S, Gebauer S, Haustein U . Cyclosporine A delays wound healing and apoptosis and suppresses activin beta-A expression in rats. Eur J Dermatol 1998;8:104–13
Nuzzi R, Cerruti A, Finazzo C . Cyclosporine C: a study of wound-healing modulation after trabeculectomy in rabbit. Acta Ophthalmol Scand 1998;227 (Suppl):48–9.
Massague J . The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597–641
Roberts A, Sporn M, Assoian R, Smith JJ Roche N . Transforming growth factor beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167–71
Critchlow M, Bland Y, Ashhurst D . The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone 1995;16:521–7
Cordeiro M, Reichel M, Gay J D'Esposita F, Alexander R, Khaw P . TGF-131, -132 and -133 in vivo: effects on normal and mitomycin-C modulated conjunctival scarring. Invest Ophthalmol Vis Sci 1999;40:1975–82
Cordeiro M, Bhattacharya S, Schultz G, Khaw P . TGF-131, -132 and -133 in vitro: biphasic effects on Tenon' fibroblast contraction, proliferation and migration. Invest Ophthalmol Vis Sci 2000;41:756–63
Connor T, Roberts A, Sporn M, Danielpour D, Dart L, Michels R, et al . Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 1989;83:1661–6
Jampel H, Roche N, Stark W, Roberts A . Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990;9:963–9
Shah M, Foreman D, Ferguson M . Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 1994;107:1137–57
Shah M, Foreman D, Ferguson M . Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108:985–1002
Cordeiro M, Gay J Khaw P . Human anti-TGF-132 monoclonal antibody: a new anti-scarring agent for glaucoma filtration surgery. Invest Ophthalmol Vis Sci 1999;40:2225–34
Wu-Pong S, Weiss T, Hunt C . Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res Dev 1994;4:155–63
Adachi S, Maruyama T, Kondo T, Todoroki T, Fukao K . The prevention of postoperative intraperitoneal adhesions by tranilast, N-(3',4'-dimethoxycinnamoyl)anthranilic acid. Surg Today 1999;29:51–4
Ito S, Sakamoto T, Tahara Y, Goto Y, Akazawa K, Ishibashi T, et al . The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1999;237:691–6
Takehana Y, Kurokawa T, Kitamura T, Tsukahara Y, Akahane S, Kitazawa M, et al . Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. Invest Ophthalmol Vis Sci 1999;40:459–66
Furukawa H, Nakayasu K, Gotoh T, Watanabe Y, Takano T, Ishikawa T, et al . Effect of topical tranilast and corticosteroids on subepithelial haze after photorefractive keratectomy in rabbits. J Refract Surg 1997;13 (Suppl):S457–8.
Chihara E, Dong J, Ochiai H . Effect of TGF-131 suppressor Tranilast on filtering bleb and lOP after glaucoma surgery. Invest Ophthalmol Vis Sci 1999;40 (Suppl):abstract no. 5104.
Kim H, Peterson T, Barnes S . Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signalling pathways. Am J Clin Nutr 1998;68 (Suppl):S1418–25.
Krott R, Lebek J Grisanti S, Luke C, Esser P, Kriegelstein G . Antiproliferative effect of Genistein in cultured human Tenon-fibroblasts. Invest Ophthalmol Vis Sci 1999;40 (Suppl):abstract no. 5117.
Mietz H, Chevez-Barrios P, Feldman R, Lieberman M . Suramin inhibits wound healing following filtering procedures for glaucoma. Br J Ophthalmol 1998;82:816–20
Beardsley T . Making antisense. Sci Am 1992;3:107–8
Fakler B, Herlitze S, Amthor B, Zenner H, Ruppersberg J . Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J Biol Chern 1994;269:16187–94
Sugawa N, Ueda S, Nakagawa H, Nishino H, Nosaka K, Iwashima A, et al . An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. J Neurooncol 1998;39:237–44
Wilson C, Szostak J . In vitro evolution of a self-alkylating ribozyme. Nature 1995;374:777–82
Moore M . Exploration by lamp light. Nature 1995;374:766–7
Bartel D, Szostak J . Isolation of new ribozymes from a large pool of random sequences. Science 1993;261:1411–8
Altman S . RNA enzyme-directed gene therapy. Proc Natl Acad Sci USA 1993;90:10898–900
Dorai T, Kobayashi H, Holland J Ohnuma T . Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol 1994;46:437–44
Drenser K, Timmers A, Hauswirth W, Lewin A . Ribozyme-targeted destruction of RNAs associated with ADRP. Invest Ophthalmol Vis Sci 1998;39:681–9
Lewin A, Drenser K, Hauswirth W, Nishikawa S, Yasumura D, Flannery J, et al . Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nature Med 1998;4:967–71
Ren X, Schultz G . Reduction of transforming growth factor beta-1 protein in cells transfected with plasmids expressing hammerhead and hairpin ribozymes. Invest Ophthalmol Vis Sci 1999;40 (Suppl):46.
Medications And Their Potential To Cause Increase 'Conjunctival Congestion'
List of Drugs that may cause 'Conjunctival congestion'Advertisement
Updated on November 16, 2023 This section presents medications that are known to potentially lead to 'Conjunctival congestion' as a side effect." It's important to note that mild side effects are quite common with medications. Please be aware that the drugs listed here are individual medications and may be part of a broader combination therapy. This information is meant to be a helpful resource but should not replace professional medical advice. If you're concerned about 'Conjunctival congestion', it's best to consult a healthcare professional. In addition to 'Conjunctival congestion', other symptoms or signs might better match your side effect. We have listed these below for your convenience. If you find a symptom that more closely resembles your experience, you can use it to identify potential medications that might be the cause.Advertisement
proparacaine Find drugs that can cause other symptoms like 'Conjunctival congestion' Blepharoconjunctivitis , Chemical conjunctivitis , Chronic conjunctivitis , Conjunctival bleb , Conjunctival cyst , Conjunctival discharge , Pterygium , Conjunctival disorder , Conjunctival follicles , Conjunctival irritation , Conjunctival ulcer , Conjunctival xerosis , Conjunctivitis , Conjunctivitis allergic , Conjunctivitis bacterial , Conjunctivitis exacerbated , Conjunctivitis infective , Conjunctivitis papillary , Follicular conjunctivitis , Keratoconjunctivitis , Other conjunctivitis , Subconjunctival cyst References
↑
New Forecast For Bullous Pemphigoid Therapies Market 2024: Set To Achieve Significant Value By 2030
(MENAFN- The Express Wire) Bullous Pemphigoid Therapies Market Insights 2023: Watch on share analysis of the key market participants in global Bullous Pemphigoid Therapies market, their product portfolio, Growth Rate, research priorities, and forecast to 2030.
The research report on the " Bullous Pemphigoid Therapies Market " [2023-2030] delves into an extensive analysis of the elements that exert their influence on the market's course. Venturing into the realm of advancements, research and development investments, evolving patterns in consumption, and the broadening array of applications that are shaping the market's trajectory, this report offers a comprehensive perspective. Furthermore, it dissects the ever-changing economic dynamics surrounding the Bullous Pemphigoid Therapies Market, poised to impart a significant impact on its path. Derived from a rigorous undertaking of primary and secondary research, this detailed market investigation culminates in a profound grasp of the Bullous Pemphigoid Therapies market's intricacies. Beyond a comprehensive depiction of current and future market aspirations, the report also undertakes a competitive scrutiny of the sector, characterized by its applications, types, and regional shifts. The report goes the extra mile in presenting an intricate portrayal of the historical and contemporary accomplishments of notable enterprises.
Between 2023 and 2030, the Global Bullous Pemphigoid Therapies Market is poised to experience substantial growth. The market has maintained a steady upward trajectory in 2021 and is projected to continue this ascent over the forecasted period, driven by the increasing implementation of strategies by prominent industry players. Ask for a Sample Report
Report Spanning across - 116 Pages
Bullous Pemphigoid Therapies Market Report Revenue by Type ( Steroid Creams, Immune Suppressants, Antibiotics ), Forecasted Market Size by Application ( Initial Phase, Active Treatment Phase, Reducing Phase, Maintenance Phase )
TOP COMPANIES/MANUFACTURERS Dominating the Global Bullous Pemphigoid Therapies Market are listed below:Get a Sample Copy of the Bullous Pemphigoid Therapies Market Report 2023
Market Analysis and Insights: Global Bullous Pemphigoid Therapies MarketBullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Incidence figures are not available for most parts of the world but BP appears to be rarer in the Far East. Bullous pemphigoid is usually a disease of the elderly but it can also affect younger people and children. Both sexes are similarly affected.
The global Bullous Pemphigoid Therapies market was valued at USD million in 2020 and it is expected to reach USD million by the end of 2030, growing at a CAGR of Percent during 2021-2030. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.Global Bullous Pemphigoid Therapies Market: Drivers and Restrains
The research report has incorporated the analysis of different factors that augment the market's growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2018 to 2030. This section mentions the volume of production by region from 2016 to 2030. Pricing analysis is included in the report according to each type from the year 2016 to 2030, manufacturer from 2016 to 2021, region from 2018to 2021, and global price from 2018 to 2030.
A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert's opinions have been taken to understand
Comments
Post a Comment